Customized endovascular repair for complex aortic aneurysms
Official title: Duke Customized Aortic Aneurysm Repair With Endovascular Stent-grafts - Duke CARES Trial
Run by Duke University · NCT07064460 · Data updated 2026-11-12
This trial tests whether surgeon-modified endovascular stent-grafts can safely treat people with complex abdominal or thoracoabdominal aortic aneurysms who are high risk for open surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Duke University Academic / other |
| Locations | 1 site (Durham, North Carolina) |
| Status | Recruiting |
| Started | January 13, 2026 |
| Main results expected | December 11, 2030 |
| Study ends | December 11, 2031 |
| Registry record updated | February 4, 2026 |
| Trial ID | NCT07064460 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with juxtarenal, pararenal, paravisceral, or thoracoabdominal aneurysms who are considered high risk for open surgical repair and have anatomy suitable for a physician-modified endovascular graft.
✕Probably not a fit
Patients whose aortic anatomy is unsuitable for endovascular repair, who are good candidates for standard open repair, or who have prohibitive comorbidities or limited life expectancy are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Duke CARES uses commercially available stent-grafts that surgeons modify to match each patient’s anatomy and then place them endovascularly to repair juxtarenal, pararenal, paravisceral, or thoracoabdominal aneurysms. Participants are high-risk for open surgery and will be followed with imaging and blood tests at acute, 30 days, 6 months, 12 months, and annually up to five years to track technical success, treatment success, and major adverse events. The protocol includes a main statistical cohort for standard cases and a non-statistical cohort to collect data on patients with life-threatening aortic disease who lack other options. Investigators will use the data to inform patient selection, device design, operative techniques, and follow-up regimens.
Why it matters
Potential benefit: If successful, this approach could provide a less invasive repair option for high-risk patients, lowering perioperative complications and shortening recovery compared with open surgery.
How similar studies have gone: Surgeon-modified endografts and physician-modified fenestrated/branched approaches have shown promising results in registries and case series but lack large randomized trials comparing them to commercial devices.
Who can join: the full rules
Show full inclusion / exclusion criteria
MAIN COHORT INCLUSION CRITERIA: * A participant may be entered into the study if the participant has at least one of the following: An aneurysm with a maximum diameter of \> 5.5 cm or 2 times the normal diameter just proximal to the aneurysm using orthogonal (i.e, perpendicular to the centerline) measurements; Aneurysm with a history of growth \> 0.5 cm in 6 months; Saccular aneurysm deemed at significant risk for rupture; Symptomatic aneurysm; Ruptured aneurysm AND * Extent of aorta to be treated: juxtarenal, pararenal that include 1 or 2 renal and/or accessory renal arteries, paravisceral that includes celiac artery and/or superior mesenteric artery, and/or thoracoabdominal * High risk of morbidity and mortality with open surgical repair as defined by: a. Anatomic Criteria (Previous abdominal surgery; Previous thoracotomy; Previous aortic surgery) b. Physiologic Criteria (ASA Category III or higher; Age \>70 years; Previous myocardial infarction, coronary artery disease, or coronary artery stent; Coronary stress test with a reversible perfusion defect; Congestive heart failure (CHF); Chronic obstructive pulmonary disease (COPD)) * Iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices or accessories, with or without use of a surgical conduit * Nonaneurysmal aortic segment proximal to the aneurysm (neck) with a minimum neck length of 25 mm (Diameter in the range of 18 mm - 42 mm; Angle less than 60o relative to the axis of the aneurysm; Angle less than 60o relative to the axis of the suprarenal aorta); * Minimum branch vessel diameter greater than 5 mm * Iliac artery distal fixation site greater than 20 mm in length and diameter in the range of 9 mm - 21 mm (for use of ZFEN) * Contralateral iliac artery distal fixation site greater than 20 mm in length and diameter in the range of 7.5 mm - 20 mm. * Age: ≥ 18 years old * Life expectancy: \> 2 years EXCLUSION CRITERIA: GENERAL EXCLUSION CRITERIA: * Able to be treated in accordance with the instructions for use with a currently marketed endovascular prosthesis * Unwilling to comply with the follow-up schedule * Inability or refusal to give informed consent by subject or legal representative * Pregnant or breastfeeding * Prefers to receive treatment at another hospital with access to a non-physician modified endovascular prosthesis * Refusal of blood transfusions for religious or personal reasons * Participation in another investigational clinical or device trial, with the exception of another investigational endovascular stent-graft protocol or percutaneous aortic valve protocol, not encompassed by the IDE protocol and performed remotely from the fenestrated procedure (\> 30 days). Examples include remote (\>30 days) participation in a thoracic, abdominal or iliac branch device trial, or participation in a percutaneous aortic valve trial. * Mycotic aneurysm or evidence of active systemic infection MEDICAL EXCLUSION CRITERIA: * Known sensitivities or allergies to the materials of construction of the devices, including nitinol (nickel, titanium), polyester, polypropylene, gold, stainless steel, and/or solder (tin, silver). * Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed * Uncorrectable coagulopathy * Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment • Morbid obesity (BMI ≥ 40 or BMI 30-39.9 with comorbidities) * Major surgical or interventional procedure unrelated to the treatment of the aneurysm planned \< 30 days of the endovascular repair * Unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina) * Baseline creatinine greater than 2.0 mg/dL * History of connective tissue disorders (e.g., Marfan Syndrome, Ehler's Danlos Syndrome) * Deemed a high risk due to significant comorbidities, adjudicated by severity according to the Society for Vascular Surgery reporting standards for endovascular aortic repair involving the renal-mesenteric arteries ANATOMICAL EXCLUSION CRITERIA: * Thrombus or excessive calcification within the neck of the aneurysm * Presence of significant thrombus and/or excessive calcification within the intended proximal or distal seal zone of the aneurysm. * Branch stenosis \> 75% (if left untreated) * Anatomy that would not allow maintenance of at least one patent hypogastric artery * Inadequate femoral or iliac access to accommodate the required delivery systems. * Requirement for iliac conduit in cases of inadequate femoral/iliac access * Absence of a suitable non-aneurysmal segment of distal thoracic aorta and significant aortic tortuosity. * Target vessel anatomy not compatible with fenestrated or branched stent graft incorporation, including vessels with severe stenosis, tortuosity and/or insufficient size to accommodate stent graft placement. * Early target vessel bifurcation precluding safe or effective stent graft placement. * Unsuitable iliac artery fixation site and/or anatomy for iliac limb extension or iliac branch device placement, as defined by the device instructions for use Note: Patients with life-threatening aortic disease who have no acceptable surgical or endovascular alternatives will be allowed to receive treatment under this IDE in the non-statistical cohort Non-statistical Cohort This cohort will include patients who meet the inclusion criteria and meet any of the above exclusion criteria\* with the exception of the following: * Able to be treated in accordance with the instructions for use with a currently marketed endovascular prosthesis * Subject prefers to receive treatment at another hospital with access to a custom-made endovascular prosthesis * Refusal to give informed consent by the subject or legal representative. Note: Inability to consent prior to surgery will not be exclusionary if it is for life-saving measures. * Known sensitivities or allergies to the materials of construction of the devices will be allowed in a life-threatening situation where the patient would not survive open surgery.
Where it's running
-
Duke University Health System
Durham, North Carolina, United States Recruiting
Study contacts
- Principal investigator: Chandler Long, MD — Duke University
- Study coordinator: Ellen R Burkett, MSHS
- Email: ellen.burkett@duke.edu
- Phone: 9196811878
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Improving Medication Adherence for Recently Diagnosed Cancer Patients
This pilot tests whether a pharmacist-led program plus the Medisafe app helps people with newly diagnosed cancer who take multiple medicines stick to their treatment plans.
-
emPath platform pilot to link and keep adults with opioid use disorder in care in Durham
This pilot tests a mobile app and telemedicine approach to help adults with opioid use disorder start and stay in MOUD through community outreach in Durham, NC.
-
FlexED: A digital program to help young women see thoughts and feelings about their body in a friendlier way
This trial tests a smartphone-based, gamified ACT-inspired program called FlexED to help young women and girls at risk for eating disorders see how they think and feel about their bodies, and to see if it can be feasibly spread to more people.
-
Removing the ripcord from a glaucoma drainage device after 3 months
This study tests whether removing the ripcord from an implanted glaucoma drainage device changes eye pressure for adults with open-angle glaucoma.
-
Lupus Nephritis Care Pathway
A small group of adults with lupus nephritis will try a team-based care path that uses telemedicine and pharmacist-led support to help manage their treatment and see if it improves adherence and outcomes.
-
Temporal Interference Brain Stimulation for adults with drug-resistant focal epilepsy during stereo-EEG monitoring
This study tests whether a non-invasive Temporal Interference brain stimulation can reduce abnormal brain activity in adults with drug-resistant focal epilepsy who are undergoing stereo-EEG monitoring.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.